Psychedelic-assisted psychotherapy: The Australian and general practice perspective

Area of Science:

• Psychiatry
• Pharmacology
• Psychotherapy

Background:

• Australia's Therapeutic Goods Administration down-scheduled two psychedelic medicines in July 2023.
• Psychotherapeutic treatment with these medicines is now accessible in the private sector.
• General practitioners (GPs) can refer patients with treatment-resistant depression or PTSD.

Purpose of the Study:

• To guide GPs in understanding psychedelic-assisted psychotherapy within the Australian context.
• To outline patient expectations and the GP's role in this emerging treatment modality.

Main Methods:

• Review of the Australian regulatory landscape for psychedelic medicines.
• Discussion of clinical applications for treatment-resistant depression and PTSD.
• Consideration of the GP's role in patient referral and management.

Main Results:

• Psychedelic medication facilitates psychotherapy by enabling access to subconscious emotions, thoughts, beliefs, and traumatic memories.
• Clinical trials indicate substantial effect sizes for psychedelic-assisted therapy.
• Ongoing research is refining indications, efficacy, and safety profiles.

Conclusions:

• Psychedelic-assisted psychotherapy offers a powerful new treatment option for specific mental health conditions in Australia.
• The treatment is currently available privately for patients with treatment-resistant PTSD and depression.
• Patient suitability, safety, and response variability are critical considerations for psychedelic treatment.